Stockreport

New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

GSK plc American Depositary Shares (Each representing two Ordinary Shares)  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTDTwo doses of vaccine in immunoco [Read more]